National and Kapodistrian University of Athens
Επίδραση της αναστολής του μετατρεπτικού ενζύμου αγγειοτενσίνης σε δείκτες αποπτωτικής δραστηριότητας στη στεφανιαία κυκλοφορία και συσχέτισή τους με την επαναστένωση εντός στεφανιαίων ενδοπροσθέσεων, σε ασθενείς οι οποίοι έχουν υποβληθεί σε διαδερμική στεφανιαία παρέμβαση
Abstract
dc:descriptionEffect of Angiotensin Converting Enzyme Inhibitors on In-Stent Restenosis andRelation to Plasma Apoptosis Signaling MoleculesTheory: Angiotensin-converting enzyme inhibitors have been reported to inhibit instentrestenosis. To assess the effect of angiotensin-converting enzyme inhibition onin-stent restenosis and its relation to apoptosis, we studied patients with chroniccoronary artery disease and significant stenosis in left anterior descending coronaryartery.Methods:116 patients with chronic coronary artery disease who required stentimplantation in the left anterior descending coronary artery or a major diagonal branchwere studied. Patients were randomized to receive angiotensin converting enzymeinhibitors orally (n = 58) or a placebo (n = 58). Drug therapy was initiated 1 weekbefore initial stenting and continued for 6 months. Plasma levels of the apoptoticsignaling molecules soluble Fas ,soluble Fasligandand sTRAIL obtained from blooddrawn from the left anterior descending coronary artery were measured just beforeinitial stenting and 6 months later, at the time of repeat coronary angiography.Results: In-stent restenosis was present in 9.3% of patients in the ACE inhibitor groupand 25.6% of patients in the placebo group (p =0.047). Mean late luminal loss was0.15[0.12-0.20]mm in the ACE inhibitor group and 0.22 [0.14-0.26] mm in the placebogroup (p = 0.002). There were no significant differences in plasma soluble Fas orsoluble Fas ligand levels at baseline. At 6 months, the change in plasma soluble Faslevel was significantly higher in the quinapril group (0.72 ±1.24 ng/ml) than in theplacebo group (0.28 ± 0.72 ng/ml)(p =0.024). The change in plasma soluble Fas ligandlevels at 6 months was significantly higher in the quinapril group (7.43 ±12.2 pg/ml)than in the placebo group (0.06 ± 6.8 pg/ml) (p =0.002).Also for the sTRAIL levelsthere was significant difference;in the ACE inhibitor group values were: 104[78-139]pg/ml vs 63[45-100] pg/ml, in the placebo group (P<0.001)Conclusion: the angiotensin-converting enzyme inhibitors leads through thesignificant increase of sFas, sFasL and sTRAIL plasma levels in important inhibitionof in-stent restenosis and reduction of the late lumen loss phenomenon afterpercutaneous intervention.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2014
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Panagopoulou, Vasiliki
- Παναγοπούλου, Βασιλική
Subjects
dc:subject × 10Rights
dc:rights- Statement dc:rights
-
- BY_NC_SA
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/42537